Cantor Fitzgerald raised the firm’s price target on Tenet Healthcare (THC) to $177 from $168 and keeps an Overweight rating on the shares. Tenet confirmed 2025 EBITDA growth, and the stock outperformed the market as that confirmation was close enough to “blessing” consensus and was more bullish than anticipated, the analyst tells investors in a research note. The firm has confidence that Tenet can continue to outperform the market and grow from their current valuation which is cheap against historical and peers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $217 from $197 at UBS
- Tenet Healthcare price target raised to $183 from $174 at RBC Capital
- Tenet Healthcare Reports Strong Q3 Results and Raises Outlook
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- Tenet Healthcare reports Q3 adjusted EPS $2.93 vs. $1.44 last year